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Abstract. Ankyrin mediates the attachment of spec-
trin to transmembrane integral proteins in both
erythroid and nonerythroid cells by binding to the
(3-subunit of spectrin. Previous studies using enzymatic
digestion, 2-nitro-5-thiocyanobenzoic acid cleavage,
and rotary shadowing techniques have placed the spec-
trin-ankyrin binding site in the COOH-terminal third
of S-spectrin, but the precise site is not known. We
have used a glutathione S-transferase prokaryotic ex-
pression system to prepare recombinant erythroid and
nonerythroid /3-spectrin from cDNA encoding approxi-
mately the carboxy-terminal half of these proteins.
Recombinant spectrin competed on an equimolar basis
with 125I-labeled native spectrin for binding to erythro-
cyte membrane vesicles (IM), and also bound anky-
rin in vitro as measured by sedimentation velocity ex-
periments. Although full length 0-spectrin could
inhibit all spectrin binding to IOVs, recombinant
a-spectrin encompassing the complete ankyrin binding
domain but lacking the amino-terminal half of the
molecule failed to inhibit about 25% of the binding
capacity of the IOVs, suggesting that the ankyrin-
independent spectrin membrane binding site must lie
PECTRIN, the major component ofthe erythrocyte mem-
brane cytoskeleton, is a heterodimer composed of two
subunits a,
￿
of 280,000 and 246,000 D respectively
(Coleman et al., 1989 ; Sahr et al., 1990; Winkelmann et al.,
1990). Each subunit is composed predominantly of multiple
106 amino acid residue repeats, c-spectrin containing 22
such repeats and 9-spectrin 17 repeats. Each subunit also
contains regions of nonhomologous sequence, and the aver-
age repeat-to-repeat sequence identity is -30%. The pri-
mary linkage of spectrin to the membrane in erythrocytes is
mediatedby the bindingof0-spectrinwith ankyrin. Inherited
defects in the linkage of spectrin to ankyrin causes reduced
erythrocyte stability and hemolytic disease in both mice
(White et al., 1990) and humans (Lux et al., 1990; Lambert
et al., 1990). The recognition that analogues ofboth spectrin
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in the amino-terminal half of (3-spectrin. A nested set
of shortened recombinants was generated by nuclease
digestion of O-spectrin cDNAs from ankyrin binding
constructs. These defined the ankyrin binding domain
as encompassing the 15th repeat unit in both erythroid
and nonerythroid S-spectrin, amino acid residues
1,768-1,898 in erythroid a-spectrin. The ankyrin bind-
ing repeat unit is atypical in that it lacks the con-
served tryptophan at position 45 (1,811) within the re-
peat and contains a nonhomologous 43 residue
segment in the terminal third of the repeat. It also ap-
pears that the first 30 residues of this repeat, which
are highly conserved between the erythroid and
nonerythroid S-spectrins, are critical for ankyrin bind-
ing activity. We hypothesize that ankyrin binds
directly to the nonhomologous segment in the 15th re-
peat unit of both erythroid and nonerythroid S-spec-
trin, but that this sequence must be presented in the
context of a properly folded spectrin "repeat unit" struc-
ture. Future studies will identify which residues within
the repeat unit are essential for activity, and which resi-
dues determine the specificity of various spectrins for
different forms of ankyrin.
and ankyrin are present in probably all cell types, and that
ankyrin can link a wide variety of integral membrane pro-
teins to the cytoskeleton including Na,KATPase (Nelson
and Veshnock, 1987; Morrow et al ., 1989), the voltage gated
sodium channel (Srinivasan et al., 1988), and others (Bour-
guignon et al ., 1986; Kalomiris and Bourguignon, 1988),
has heightenedthe importanceofunderstanding the way spec-
trin and ankyrin interact.
The location and nature ofthe ankyrin binding site in spec-
trin are not well defined. Previous studies using enzymatic
digestion and 2-nitro-5-thiocyanbenzoic acid (NTCB) cleav-
age identified a 50-kD fragment arising from the 000H-
terminal third of O-spectrin which could inhibit the binding
of spectrin to stripped erythrocyte membranes (Morrow et
al., 1980) . Rotary-shadowed electron micrographs of spec-
1. Abbreviations used in thispaper: IOV, spectrin and actin free erythrocyte
inside-out vesicles; NTCB, 2-nitro-5-thiocyanbenzoic acid.
267trin-ankyrin complexes wereconsistent with this assignment
(Tyler et al ., 1980). In addition, ankyrin was found to bind
with higher affinity to spectrin tetramers and oligomers com-
pared with dimeric spectrin, suggesting that the ankyrin
binding site might be sensitive to conformational changes
emanating from the spectrin self-association site (Cianci et
al., 1988) .
In the present study, as a first step to elucidating the molec-
ular mechanisms by which spectrin-ankyrin binding may be
controlled, we have used deletional analysis of recombinant
0-spectrin to define precisely the structural determinants of
the ankyrin binding domain. We find that ankyrin binding re-
quires nearly the complete 15th repetitive unit of 0-spectrin
(residues 1,768-1,898), and that it is highly sensitive to dele-
tions that appear to modify the conformation of this repeat.
We also provide evidence that a similar ankyrin binding site
exists in recombinant human nonerythroid 0-spectrin (a-
fodrin), and that an ankyrin independent membrane binding
site exists in the amino-terminal half of (3-spectrin. Collec-
tively, these results provideamolecular framework for under-
standing the complexity of the spectrin-ankyrin interaction
and its apparent regulation by allosteric and posttranslational
mechanisms.
Materials andMethods
Construction ofFull-length and Truncated
(328-Spectrin Expression Plasmids
The methods used to construct expression plasmids have been describedby
Maniatis and colleagues (1982). All enzymes and oligonucleotides were
purchased from New England Biolabs. The pGEX vectors were the gener-
ous gift of Dr. James M. Anderson, Yale University, New Haven, CT, and
may presently bepurchased from Pharmacia LKB Biotechnology, Inc. (Pis-
cataway, NJ). All other reagents were of analytical grade and purchased
from Sigma Chemical Co., St. Louis, MO.
Plasmid pBR322028 (Winkelmannet al., 1988), which contains -40%
of the coding sequence through the COOH terminus ofhuman erythrocyte
0-spectrin, was digested with Ncol and blunt ended by treatment with
Klenow fragmentof DNA polymerase I and deoxynucleoside triphosphates
(dNTPs) as shown in Fig. 1. A BamHI linker (d(CGGATCCG)) was ligated
onto the blunt end with T4 DNA ligase and the resultant plasmid was se-
quentially digested with BamHI and EcoRI. A 2.494-kb 028 restriction
fragment was purified from an agarose gel and ligated into complementary
sites in pGEX-3X. Truncated forms of 028 (see Fig. 2) were constructed
by digesting pGEX-3X028 with the appropriate restriction endonuclease,
treating with klenow (for XhoI, NdeI) or T4 DNA polymerase (for SphI)
and dNTPs, and inserting a nonsense codon linker, d(CTAGCTAGCTAG),
containing a unique NheI site. Construction of the ScaI plasmid required
isolation of the desired restriction fragment from a partial ScaI digest.
Sequential carboxy-terminal truncations (Fig. 5 a) were constructed by
digestion of 028XhoI with the NheI followed by time-dependent digestion
with nuclease Bal 31 at 30°C. Reactions were terminated by extraction with
phenol:chloroform (1:1) saturated with 10 mM Tris, 1 mM EDTA, pH 8 (TE
buffer). Digested plasmids were blunt ended with Klenow, and NheI non-
sense codon linkers were ligated onto this site. The resultant constructs
were digested with NheI and BamHl, and truncated restriction fragments
were purified and ligated onto 028Xhol that had sequence between the
BamHI and NheI sites removed.
Sequential amino-terminal truncations (Fig. 5 b) were constructed by
digesting 028Xho I-5C-Scal with BaniHI followed by digestion with nu-
clease Bal 31 and treatment with Klenow. A BamHI linker, d(CGCGGA-
TCCGCG), was ligated into this site, truncated BamHI-EcoRI restriction
fragments purified, and ligated into complementary sites in pGEX-IN, -2T,
and -3X vectors.
028Sca I-4N-SphI and 028Sca I-ION-NdeI (Fig. 6) were constructed by
digesting 028XhoI-5C-ScaI-4N and 028XhoI-5C-ScaI-l0N with Sphl and
NdeI, respectively. Both constructs were blunt ended and nonsense codon
linkers were ligated into these sites. 028XhoI-5C-Sphl (Fig. 6) was con-
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structed by removal of sequence between the BamHI and Sphl sites of
028Xhol-5C, treatment with T4DNA polymerase, and ligation ofthe blunt-
ended construct. Some S28-constructs in pGEX-3X were subcloned into
pGEX-2T by digestion with BamHI, followed by Klenow treatment, EcoRl
digestion, and ligation of the BamHI (Blunt)-EcoRl restriction fragment
into pGEX-2T. The ,8-fodrin expression plasmid was constructed by sub-
cloning a 1.589-kb 0-fodrin EcoRI restriction fragment, originally isolated
froma human endothelial cellcDNA library, into pGEX-3X. Thecomplete
characterization ofthis clone willbe reported separately (Chang, J.-G., and
B. G. Forget, manuscript inpreparation). Its identity as a bonafide 0-fodrin
clone has been verified by a comparison of the predicted amino acid se-
quence of overlapping genomic and cDNA clones with direct protein se-
quence obtained from purified human brain 0-spectrin (Green, L. A. D.,
A. S. Harris, D. W. Speicher, and J. S. Morrow, unpublished data).
Expression and Purification ofRecombinant
5-28-Spectrin Fusion Proteins
Recombinant proteins were expressed and purified from Escherichia coli
as described (Smith and Johnson, 1988) . Overnight cultures of E. colt
(JM101 or W3110) transformed with pGEX-028 constructs were diluted
1:10 with Luria broth medium and grown for 1 h at 37°C. Isopropyl-
thiogalactopyranoside (1 mM)was addedandafter 3-4 hofgrowth, bacteria
were pelleted and resuspended in 1:50 culture volume ofa sonication buffer
containing 50 mM Tris, 50 mM NaCl, 1 mM EDTA, and 0.15 mM PMSF,
pH 8.0 at 4°C. Induction was maximal at 3-4 h and fusion proteins com-
prised 20-80% oftotal bacterial protein, as determined by densitometry of
Coomassie blue-stained SDS gels (not shown). All subsequent steps were
performed at 0-4°C. Bacteria were treated with 1 mg/ml lysozyme for 30
min and then 10,ug/ml leupeptin, 1 mM PMSF, 1 mM IYTT, 1 mM EDTA,
1 mM benzamidine, 10 mg/ml aprotinin, and 1 jig/ml pepstatin A were
added. The suspension was frozen on dry ice, thawed at 30°C, and in-
cubated with Triton X-100 (196), deoxyribonuclease I (0.1 mg/ml), and
M9C12 (10 mM) for 30 min. Diisopropylfluorophosphate (0.5 mM) was
added and the suspension was sonicated with a sonifier (70 W; Branson
Sonic Power, Danbury, CT) for 30 s. The lysate was centrifugedat 48,000 g
for 20 min and the supernatant applied to a 2-4 ml reduced glutathione
agarose column. The column was washed with 25 ml of phosphate buffer
containing 130 mM NaCI, 7.2 mM Na2HP04-71120, 2.8 mM Na2H2PO4,
1 mM DTT, 0.1 mM PMSF, 1 mM EDTA, pH 7.5 (PBSI), and 0.596 Triton
X-100, followed by 100 ml ofPBSI and 25 ml sonication buffer. Bound fu-
sion protein was eluted with sonication buffer containing 5 mM reduced
glutathione. For removal ofthe glutathione transferase tail, proteins bound
to the glutathione column were eluted by the addition of 250 U of human
plasma thrombin in 50 mM Tris, 150 mM NaCl, 2.5 mM CaC12, pH 8.0
for 1 h at 37°C. Samples were concentrated by centrifugation in centricon
microconcentrators (Amicon Corp., Danvers, MA). Recombinant proteins
that remained insoluble after lysing the bacteria were solubilized in freshly
prepared 8 M urea, 50 mM Tris, 1 mM DTT, 1 mM EDTA, pH 8.0 at room
temperature for 1 h. The urea extract was diluted 1:10 in sonication buffer
and applied to the glutathione agarose column as above.
Erythrocyte Inside-Out Vesicle (IOV) Binding Studies
Spectrin and actin-free erythrocyte vesicles (IOUs), resealed ghosts, and
1251-labeled spectrin tetramer were prepared as before (Morrow et al.,
1980; Howe et al., 1985). Spectrin tetramer was iodinated using immobi-
lized lactoperoxidase and glucose oxidase (Bio-Rad Enzymobeads, Rich-
mond, CA). Fusion proteins were tested for ankyrin binding inhibitory ac-
tivity by incubation with 40 hg IOV protein at 25°C for 30 min, followed
by incubation with radiolabeled spectrin for 2 h. Unbound spectrin was
separated from vesiclesby sedimentation througha5% sucrosecushion and
both the bound and unbound fractions were quantitated by y counting (1282
Compugamma CS gamma counter; LKB Instruments, Gaithersburg, MD).
Sedimentation Velocity Studies
Humanerythrocyteankyrin was preparedbyhigh salt extraction ofIOUs fol-
lowed by DEAE-cellulose chromatography (Tyler et al., 1980). Recombi-
nant spectrin proteins (15-25 jig), iodinated with Na [1251] in the presence
of Enzymobeads, were incubated with 10012g of ankyrin in isoKCI buffer
(130 mM KCI, 20 mM NaCl, 10 mM Tris, 1 mM EDTA, 0.1 mM PMSF,
5 mg/ml leupeptin, 0.5 mM 0-mercaptoethanol) for 5 h at 0-4°C. Samples
were centrifuged at 200,000 g for 20 h at 4°C in a 5-20% sucrose gradient
in isoKC1. Approximately 0.35-ml fractions were collected and assayed for
radioactivity by -y counting. Protein content was assayed by OD280 and
268SDS-PAGE. Gradients were calibrated with equine heart cytochrome C
(1.83S), bovine serum albumin (4.315), rabbit skeletal muscle aldolase
(7.35S), and bovine liver catalase (11.3S) .
OtherProcedures
SDS-PAGE and protein transfer to nitrocellulose (Western blots) were per-
formed as described (Towbin et al., 1979; Laemmli, 1970). SDS-PAGE
gels were stained with Coomassie brilliant blue. Antibodies were prepared
in New Zealand white rabbits using the isolated ,B-spectrin subunit or the
COOH-terminal phosphorylated NTCB fragment eluted from SDS-PAGE
gels (Mische, 1988) . Western blots were developed by incubation with ...I-labeled staphylococcal protein A (Lux et al., 1990) followed by au-
toradiofluorography. Protein determinations were by the method of Lowry
et al. (1951),with bovine serum albumin used as a standard. DNAsequenc-
ing was performed using a Sequenase kit version 2.0 (United States Bio-
chemical Corp., Cleveland, OH).
Results
ExpressionofRecombinant0-Spectrin Proteins
in E. coli
A 2.679-kb 0-spectrin cDNA, 028 (amino acid residues
1,333-2,137, numbering according to Winkelmann et al.,
1990) was used for these studies since the encoded sequence
extended beyond the boundaries of the 50-kD NTCB frag-
ment previously shown to contain some or all ofthe ankyrin
binding site (Morrow et al., 1980). A 028 Ncol-EcoRl re-
striction fragment encoding from the center of 0-spectrin re-
peat 11(1397) to the carboxy terminus(2137) was subcloned
into a glutathione S-transferase fusion protein expression
vector as shown schematically in Fig. 1 . The 028(1397-2137)
construct was truncated by insertion of translation termina-
tion codons at restriction endonuclease sites thought to be
close to or distant from the ankyrin binding site (Fig. 2).
These constructs allowed a determination of the general
boundaries of the ankyrin binding site.
Induction ofbacteria containing pGEX-3X028(1397-2137)
constructs with isopropyl-thiogalactopyranoside resulted in
the appearance of fusion protein bands not present in unin-
duced bacteria and at the predicted molecular weights (data
not shown). Thesefusion proteinswere purified directly from
bacterial lysates on a glutathione affinity column and ana-
lyzed by SDS-PAGE (Fig. 2). Yields ofpurified recombinant
proteins were highly variable, from 1-10 mg/liter of culture,
depending largely on the size and solubility of each protein.
Truncationat the Ndel(1865) site caused a dramatic decrease
in the solubility of this fusion protein, however, it remained
soluble after treatment with urea followed by slow dialysis
into, or dilution with isotonic buffer (isoKCI). Fragments of
spectrinhave previously been shown to recover ankyrin bind-
ing activity after treatment with denaturants (Morrow et al.,
1980).
Todemonstrate that the028 fusion proteins were expressed
in the correct reading frame and represented bonafide 0-spec-
trin, they were transferred to nitrocellulose and immuno-
blotted with anti-0-spectrin antibodies (Fig. 2). These stud-
ies also clearly indicated that most of the lower molecular
mass bands which appeared to copurify on the glutathione
column with the recombinant spectrin peptides did not react
with the anti-spectrin antibodies. All fusion proteins were
recognizedat theirpredicted relative molecular masses by an
antibody specific for0-spectrin. Moreover, as expected, only
native spectrin and the full-length 028 recombinant protein
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Figure 1. Construction of the 028-spectrin prokaryotic expression
vector. The pGEX-3X/328 vector was constructed by cloning in the
2.494-kB 0-28-spectrin cDNA restriction fragment at the EcoRI
and the BamHI cloning sites. The pGEX vectors are available in
threedifferent reading frames, pGEX-IN, -2T, and -3X. PGEX-2T
and -3X vectors contain thrombin and factor Xa protease sites in
the multiple cloning site respectively, which facilitates removal of
the glutathione S-transferase(SjM) portion of the fusion protein.
were recognizedby antibody (0-1), which was specific for the
extreme carboxy terminus of 0-spectrin. Of technical inter-
est in these studies was the small amountofproduct at 115,000
M, which appeared when the Scal(1397-1589) construct was
expressed in JM101 bacteria. This product also reacted with
the 0-1 antibody, and in separate studies was found, unlike
the truncated ScaI(1397-1589) construct product (50,000
Mr), to be competent for ankyrin binding. The genesis of
this minor read-through product was traced to nonsense sup-
pression of the stop codon inserted into the Scal(1589) site
by the JM101 bacteria, a problem that was readily eliminated
by expressing the same construct in W3110bacteria, a strain
that is nonsense suppressor defective (sup-) (Bachmann,
1983) . All subsequent experiments were carried out in the
W3110 strain of bacteria to avoid this problem.
The028(1397-2137) and028XhoI(1397-2015) Fusion
Proteins CompetitivelyInhibitAnkyrin-dependent
Spectrin-MembraneBinding
028 fusion proteins were examined for ankyrin binding ac-
tivity by their ability to compete with radiolabeled spectrinCOOH
a-spec
binding
17116 115
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Figure 2. Recombinant (328-spectrin proteins react with 0-spectrin antibodies . (a) The repetitive unit structure of erythrocyte 0-spectrin
is shown with the approximate binding sites for a-spectrin (Morrow et al ., 1980), calmodulin (Anderson and Morrow, 1987), protein 4 .1
(Becker et al ., 1990), and actin (Tyler et al . 1980) . The approximate region of ankyrin binding as deduced from earlier studies is also
depicted by the shaded bar (Morrow et al ., 1980) . The restriction endonuclease sites used to truncate the 028 cDNA are illustrated . (b)
0-Spectrin fusion proteins were expressed and purified by glutathione affinity chromatography from bacteria (E. coli W3110 unless other-
wise noted), electrophoresis on 10% SDS gels and stained with Coomassie blue . Lane 1, purified erythrocyte spectrin; lane 2, rec-028
spectrin ; lane 3, rec-028XhoI; lane 4, rec-028NdeI spectrin; lane 5, rec-028SphI spectrin ; lane 6, rec-028ScaI spectrin (expressed in
JM101) ; lane 7, rec-028Scal spectrin ; lane 8, pGEX vector (glutathione S-transferase) alone . The approximate size (kilodaltons) of stan-
dards and the major translation products are as indicated . (c) Autoradiogram of Western blot of gel shown in b, stained with polyclonal
rabbit antibodies to 0-spectrin . (d) Autoradiogram of Western blot of gel shown in b, stained with a polyclonal rabbit antibody specific
for a COOH-terminal phosphorylated peptide generated by NTCB cleavage of 0-spectrin (0-1) . Note that all 628-fusion proteins reacted
with antibodies specific for the entire 0-spectrin, and that only native spectrin and the full-length rec-028 protein reacted with an antibody
specific for the extreme carboxyAerminus of 0-spectrin . The immunoreactivity observed at -115 kD in lane 6 (rec-028ScaI) is "read
through" product due to expression inE . coli (JM101), which can suppress the termination codon inserted at the ScaI site in this construct .
No read-through product appears when this construct is expressed in W3110 E. coli (lane 7) .
for binding to erythrocyte IOV's, an interaction generally at-
tributed to ankyrin (Bennett and Stenbuck, 1979) (Fig . 3) .
Unlabeled spectrin (2.4 p,M) inhibited over 95% of the bind-
ing of ' 15I-spectrin to IOVs. In the same assay, the 028(1397-
2137) and 028-XhoI(1397-2015) fusion proteins inhibited
-75 percent ofmaximal spectrinbinding, andthe 028-NdeI-
(1397-1865), 028-SphI(1397-1790), and 028-ScaI(1397-
1589) fusion proteins were without inhibitory activity (only
the result for 028-NdeI(1397-1865) is shown) . Identical re-
sults were obtained with fusion protein concentrations up to
50 1AM and with the glutathione S-transferase protein re-
moved (data not shown), indicating that the failure of the
028(1397-2137) and028-XhoI(1397-2015) constructs to fully
inhibit spectrin binding was not due simply to a reduced af-
finity for ankyrin (also see below) . These findings, in con-
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junction with other data discussed below, suggest that an
ankyrin-independent membrane binding site(s) must reside
in the amino-terminal half of 0-spectrin .
Although the /328(1397-2137) and 028-XhoI(1397-2015)
fusion proteins could not achieve a net level of inhibition
equivalent to that of native spectrin, at low concentrations
these peptides were just as effective as native spectrin, as
shown in Fig . 4 . Spectrin, 028(1397-2137), and 028-XhoI-
(1397-2015) all demonstrated competitive inhibition of "'I-
spectrin binding to IONs, with nearly identical inhibition
constants (K) of 1-3 p,M . Conversely, 028-NdeI(1397-1865),
028-SphI(1397-1790), and 028-ScaI(1397-1589) fusion pro-
teins were inactive . This placed the carboxy-terminal boun-
dary of the ankyrin binding site between the XhoI(2015) and
NdeI(1865) sites in the 028 cDNA sequence (Fig . 2) .
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AnkyrinBindingRequires theFull 15thRepeat
Unitoffl-Spectrin
To more precisely define the carboxy-terminal sequence of
the ankyrin binding site, the pGEX-3XO28-XhoI(1397-2015)
plasmid was sequentially nuclease digested from the XhoI-
(2015) site to the inactivating Ndel(1865) site. The truncated
fusionproteins were purified and examined for inhibitory ac-
tivity in the IOV binding assay (Fig. 5 a). The truncated plas-
mids were also sequenced to define the new 3' terminus cre-
ated by the digestion. Activity was not affected by 3' deletions
until the boundaries of the 15th repeat unit were reached,
whereupon activity was abruptly abolished (028-Ndel(1397-
1865)) . This result placed the carboxy-terminal boundary of
a functionally active inhibitory peptide at amino acid 1,898
in the 0-spectrin sequence. Truncations from the amino ter-
minus of the smallest active fusion protein, 028-XhoI-5C-
(1397-1898), down to the amino-terminal Scal(1589) site did
not affect ankyrin binding activity (Figs. 2 and 5 b). How-
ever, truncation to the Sphl(1790) site abolished activity (not
shown), placing the amino-terminal boundary of the ankyrin
binding site between these two restriction sites. Therefore,
028-XhoI-5C-Scal(1589-1898) was sequentially digested
from the 5' terminus to the Sphl(1790) site, and the resulting
deletion mutants were expressed in each of three reading
frames. Their fusion proteins were purified, and those mak-
ing bonafide spectrin peptides were examined for inhibitory
activity. As shown in Fig. 5 b, progressive deletion ofamino-
terminal sequence resulted in a gradual loss ofinhibitory ac-
tivity, which rapidly became variable and then fell to null
values as the truncations approached the boundaries of the
15th repeat unit. These results suggested that the fusion pro-
tein 028-XhoI-5C-ScaI-7N(1712-1898) represented the min-
imal sequence necessary for ankyrin binding. Alternatively,
it was possible that the glutathione S-transferase fusion pro-
tein was interfering with ankyrin binding in the amino-termi-
nal deletion recombinants. Therefore, further studies were
carried out after removal of the fusion protein tail.
As shown in Fig. 6, removal oftheglutathione S-transferase
tail from028-XhoI-5C-Scal-ION(ScaI-ION(1768-1898))with
thrombin, resulted in the return ofmeasurable IOV spectrin
binding inhibitory activity to this otherwise inactive protein.
To ensure that the Scal-ION(1768-1898) protein represented
the minimal sequence required for ankyrin binding, it was
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Figure 4. Recombinant O-spectrin proteins inhibit radiolabeled
spectrin binding to IOVs with affinities equal to that of intact spec-
trin. Radiolabeled spectrin (o, o, o, 0, M, A ; 1, 11, 22, 1.2, 3.5,
6.5 kg, respectively) was incubated with IOVs in the absence or
presence of (a) spectrin, (b) rec-028 spectrin, (c) rec-028-XhoI
spectrin, or (d) rec-028-NdeI spectrin. The approximate Ks for
all active proteins (including native spectrin) ranged from 1-3 AM.
The rec-028-NdeI spectrin was inactive.
further truncated from the amino (5C-Sphl(1790)) or car-
boxy (ION-Ndel(1865)) termini and the glutathione S-trans-
ferase tails removed (Fig. 6) . Both of these truncations abol-
ished the inhibitory activity of the Scal-1ON(1768-1898)
protein, indicating that this entire sequence;was essential to
fullyinhibit spectrin-ankyrin binding. To ensure that the in-
hibitory activity that was being measured in the IOV assays
was unique to the 15th repeat unit, a recombinant protein of
equivalent size to Scal-ION(1768-1898) but encoding repeat
unit 14 was prepared . As shown in Fig. 6, this repeat 14 pro-
tein, 028-Scal-4N-Sphl(1660-1789), which included se-
quence in common with the amino end of the Scal-ION pro-
tein(1768-1898), was inactive.
Since spectrin has been shown to also bind to IOVs by an-
kyrin-independent mechanisms (Howe et al., 1985 ; Steiner
et al., 1988), itwas necessary to demonstrate that the recom-
binant proteins which were competent for inhibitory activity
in IOV binding assays were indeed able to bind ankyrin.
Therefore, active (028(1397-2137), Scal-l0N(17684898))
and inactive (4N-Sphl(1660-1789), ION-Ndel(1768-1865),
5C-SphI(1790-1898)) recombinant proteins were 1151-labeled
and assayed for direct binding to purified ankyrin by velocity
centrifugation in sucrose gradients (Fig. 7). As expected,
only the 028(1397-2137) and Scal-l0N(1768-1898) proteins
bound and comigrated with ankyrin, confirmingthe conclu-
sions of the IOV-spectrin competition assays.
ARecombinant Nonerythroid 0-Spectrin
PeptideEncompassing the 15thRepeat Also
BindsAnkyrin
Nonerythroid spectrin, or fodrin (240,000-235,000 M,) canFigure 5. The carboxy- and amino-terminal boundaries of the 0-spectrin ankyrin binding domain include repeat 15. Purified recombinant
proteins were electrophoresed on 10 (NHZ-terminal) or 7% (COOH-terminal) SDS gels, and assayed for ankyrin binding activity as de-
scribed in Fig . 3 . Approximate K;s were determined from Dixon plots . Amino acid positions within the 0-spectrin sequence are indicated
in parentheses . (a) The pGEX-3X028-Xho I construct was sequentially digested from the XhoI site to the Ndel site with Bal 31 nuclease .
The purified peptides are shown on SDS gels at the top, the location of the truncation, as determined by sequencing, is depicted at the
bottom . (b) Removal of sequence between the 5'terminus and Scal site of 028-Xhol-5C did not affect activity, therefore the 5C-ScaI con-
struct was nuclease digested from the ScaI site to the Spill site. The purified recombinant peptides and the location of the truncations is
shown as in a . -, no inhibition up to 50 pM of inhibitory peptide . * Although the 5C-Scal-10N fusion protein was inactive, removal of
the glutathione S-transferase tail with thrombin restored activity, as described below (Fig . 6) .
also bind erythrocyte ankyrin, albeit with lower affinity than
the erythrocyte protein (Harris et al., 1986) . To determine
if the ankyrin binding site in nonerythroid spectrin resided
in a similar region ofthe 0-subunit, a 0-fodrincDNA (1.589
kb) encompassing repeat 15 was expressed and purified as
a glutathione S-transferase fusion protein (90,000 D) (Fig .
8) . This 0-fodrin recombinant, which represents approxi-
mately the COOH-terminal quarter of 0-fodrin, was recog-
nized by an antibody to intact fodrin (not shown) and was
able to bind ankyrin as indicated by its comigration with
purified erythrocyte ankyrin during velocity sedimentation
(Fig . 8) . Thus, ankyrin binds to similar regions of both hu-
man erythrocyte 0-spectrin and human 0-fodrin . As shown
below (Fig . 9), the 15th repeat of these two proteins share
many similar features, which distinguish them from other
spectrin repeats .
Discussion
The data presented here indicate that ankyrin binds to the
15th repetitive unit of human erythrocyte and nonerythroid
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0-spectrin, and that the binding site requires a complete 15th
unit and some portions of the 16th unit . This conclusion is
supported by the following observations : (a) an erythroid
0-spectrin recombinant peptide which begins at the second
residue in the 15th repeat and extends 25 residues into the
16th repeat is fully active in vitro for ankyrin binding ; (b)
recombinant peptides with N112-terminal deletions 24 resi-
dues into the repeat are inactive ; (c) recombinant peptides
with COOH-terminal deletions 8 residues into the 15th re-
peat are inactive; (d) a nonhomologous 43-residue sequence
that is unique to the 15th repeat of erythroid spectrin is
highly conserved in the 15th repeat of (3-fodrin ; and (e) re-
combinant 0-fodrin peptides encompassing the 15th unit
bind ankyrin in vitro . These results are summarized in Fig . 9 .
In addition, it has been demonstrated that recombinant
0-spectrin peptides encompassing repeat 11 through the car-
boxy terminus inhibit only the ankyrin-dependent binding of
spectrin to erythrocyte membranes (IOVs), but not the
ankyrin-independent binding . Since previous studies have
found that all spectrin-membrane binding to IOVs can be
inhibited by the intact 0-spectrin subunit (Morrow et al .,
272Figure 6 . Only recombinant /3-spectrin proteins containing the complete 15th repeat unit have ankyrin binding activity. (a) Coomassie
blue-stained 15% SDSgel of(3-spectrin recombinant proteins with glutathione S-transferase fusionprotein tailsremoved. (b) /3-28XhoI-5C-
ScaI-lON was further truncatedfrom its aminoandcarboxy termini, and$28Scal-4N-SphI, whichcontained the 14th repeat unit ofa-spec-
trin, were prepared and assayed for both IOV binding inhibitory activity and for direct ankyrin binding activity (Fig . 7) .Z a
U
0
0
c
U
a
10 20 '30 0 10 20 -30
gradient fraction (top -> bottom)
Figure 7 . Recombinant 028Xhol-5C-Scal-ION spectrin binds
directly to ankyrin . Recombinantproteins with glutathione S-trans-
ferase tails removed were labeled with 121-1, incubated with (o, o)
or without (lines only) purified ankyrin and centrifuged on a 5-20%
sucrose gradient . The solid black bar indicates the migration posi-
tion of ankyrin at 6.3S, as determined by OD28o and SDS-PAGE
analysis . Counts in each fraction were normalized relative to total
counts in the gradient . (a) rec-/328 spectrin ; (b) rec-028XhoI-5C-
ScaI-lON spectrin ; (c) rec-S28Scal-ION-NdeI spectrin (o) and rec-
/328XhoI-5C-SphI spectrin (o) ; (d) rec-028Scal-4N-Sphl spectrin .
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1980), our present results imply that the ankyrin-indepen-
dent membrane binding site(s) must exist in the NHZ-termi-
nal halfof O-spectrin (repeats 1-10) . Since this is also the lo-
cation of the protein 4 .1 binding site_ (Becker et al ., 1990),
further deletional analysis studies will be required to distin-
guish the relative contributions of the 4:1 site from other
ankyrin independent membrane binding sites in erythroid
and nonerythroid a-spectrin .
The large size of the minimum ankyrin binding domain,
15,300 D, implies that both linear and conformational deter-
minants contribute to the ankyrin binding function of spec-
trin . Comparison of 15th repeat sequence with that of other
repeats that do not bind ankyrin (Fig . 9 a) revealed several
unique features, which may contribute to its ability to bind
ankyrin . The most striking difference in the 15th repeat is
the absence of the strongly conserved tryptophan at repeat
position 45 (residue 1,811) (Winkelmann et al ., 1990) . A sec-
ond difference is the presence of a highly nonhomologous
43-residue sequence in the latter half of this repeat, residues
1,823-1,865. This sequence is only 7% identical to a con-
sensus sequence derived from repeats 12-16, compared to an
average identity of 39% for repeats 12, 13, 14, and 16. Both
ofthese distinguishing features are also preserved in the 15th
repeat of 0-fodrin (Fig . 9 b), where the nonhomologous 43-
residue sequence is 51% identical to that in the erythrocyte
protein but dissimilar to other 0-fodrin repeats . The differ-
ences in amino acid sequence in these two nonhomologous
segments probably accounts for the different affinities of
erythrocyte and brain spectrin for ankyrin (Harris et al .,
1986) .
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Figure 8. A recombinant human 0-fodrin fusion
protein binds ankyrin.A0-fodrincDNA (10 D)
encompassing the 15th repeat unit was expressed
as a fusion protein and assayed for direct anky-
rin binding as described in Fig . 7. The shift in
migration of the rec-i3-fodrin 10-D protein af-
ter incubation with ankyrin (o) compared to
its migration without ankyrin (line) was repro-
duced in three separate experiments . Intact na-
tive fodrin also boundankyrin in this assay (data
not shown) . (Inset) Purified human brain fo-
drin (lane a) and recombinant 0-fodrin (10 D)
(lane b, 90 kD) were analyzed by SDS-PAGE
on a 10% gel .repeat 15
10 20 30 40 50 60 70 80 90 100
---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+------
1 IAEWKDGLNEMWADLLELIDTRMQLLAASYDLHRYFYTGAEILGLIDEKHRELPEDVGLDASTAESFHRVHTAFERDVHLLGVQVQQFQDVATRLQTAYAGEKAEA 106
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1 IAEWKDGLNEAWADLLELIDTRTQILAASYELHKFYHDAKEIFGRIQDKHKKLPEELGRDQNTVETLQRMHTTFEHDIQALGTQVRQLQEDAARLQAAYAGDKADD 106
repeat 16
110 120 130
￿
Similarity ld,-ntity
---+---------+---------+-
107 IQNKEQEVSAAWQALLDACAGRRTQ 131
￿
p-spectrin
II . :I .II .II . .IIIII . :II . .
￿
81 .1%
￿
60.3%
107 IQKRENEVLEAWKSLLDACESRRVR 131
￿
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Figure 9 (a) The 15th repeat ankyrin binding domain is atypical and contains a nonhomologous segment . Erythroid /3-spectrin repeat
units 12-16 were aligned (Winkelmann et al ., 1990), and compared to their consensus sequence. Consensus residues are depicted in bold
letters . The boxed area represents the extent ofthe ankyrinbinding rec-/328-Scal-lON protein ; hatched sections represent inactivating trunca-
tions at the Spill and Ndel sites. The solid bar indicates a 43-amino acid nonhomologous segment. (b) The 15th repeat of both erythroid
(top) and nonerythroid R-spectrin (bottom) share many similarities . Note the absence of trp 45 in both proteins, and the nonhomologous
segment in the latter third of the repeat . Presumably, the amino acid differences between 0-fodrin and O-erythrocyte spectrin shown here
account for the -100-fold lower affinity of the brain protein for erythrocyte ankyrin (compared to erythrocyte 0-spectrin ; see Harris et
al., 1986) .
A third unusual feature of the 15th repeat of /3-spectrin
emerges from a comparison of the spectrin and fodrin se-
quence (Fig. 9 b) . The first 30 residues of the 15th repeat
are unusually well conserved between R-fodrin and a-spec-
trin, being 90% identical compared to 33, 30, 53, and 60
identity for the 12th, 13th, 14th, and 16th repeats, respec-
tively (Forget, B. G ., unpublished data) . This observation,
together with the sensitivity of ankyrin binding to deletions
in this region, indicate that this portion of the 15th unit also
Kennedy et al . Spectrin-Ankyrin Binding
must be particularly important for ankyrin binding activity.
However, since recombinant peptides encompassing the 14th
unitof(3-spectrin and the initial 22 residues of the 15th repeat
do not bind ankyrin (Fig. 6), it appears that this highly con-
served sequence alone is insufficient for activity.
Collectively, these observations suggest that while the 43-
residue nonhomologous segment in the terminal third of the
15th spectrin repeat unit is probably most critical for ankyrin
binding activity, other conformational determinants provided
275NH2
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by flanking sequences are also required. The most important
of these flanking sequences appears to be the initial 30 resi-
dues inthe repeat. Algorithms predicting secondary structure
(Chou and Fasman, 1978)suggest that in the nonhomologous
segment, a-helix is largely replaced by (3-sheet or other non-
helical structure (Fig. 10), while the initial 30 residues ofthe
repeat are predicted to be strongly a-helical. The sequences
exiting the repeat are also predicted to be largely a-helical .
Truncations which abolish ankyrin binding activity in the
ScaI-ION(17684898) peptide (SphI(1790) and NdeI(1865)
are thus predicted to remove a-helical conformation. We in-
terpret these observations to mean that ankyrin binding ac-
tivity requires the nonhomologous 43-residue segment,
which must be presented in the context of a proper "spectrin
repeat" tertiary folded structure with a-helices entering and
exiting the repeat unit.
The complexityofthe ankyrin binding site and its apparent
sensitivity to conformational constraints suggests that small
deletions or post-translational modifications may significantly
alterspectrin7s ankyrin binding activity. These changes prob-
ably need not occur at sites directly involved with ankyrin
binding, since they must only impact the secondary or ter-
tiary structure ofthe 15th repeat unit. We therefore anticipate
that inherited mutations affecting spectrin-ankyrin binding
will prove to be relativelycommon, but perhaps more subtle
in theireffects than those affecting dimer-dimer self-associa-
tion (Knowles et al., 1983). At the same time, the sensitivity
of ankyrin binding to several factors within the repeat unit
suggests a structural basis for the modulation of ankyrin
binding by the oligomeric state of spectrin (Cianci et al.,
1988) or by the phosphorylation state of ankyrin (Lu et al.,
1985). Further studies using site-directed mutagenesis may
be required to identify which residues within the repeat unit
are most essential for activity, and which residues contribute
to the specificity of various spectrins for different forms of
ankyrin.
The authors wish to thank Dr. John Winkelmann (University of Minnesota)
for providing information on the /328 clone in advance of its publication,
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